Identification of WISP1 as a novel oncogene in glioblastoma

DI JING1*, QIAN ZHANG2*, HAIMING YU3, YAJIE ZHAO4 and LIANGFANG SHEN1

1Department of Oncology Radiotherapy, Xiangya Hospital of Central South University, Changsha, Hunan 410008; 2Teaching and Research Section of Surgery, Xiangnan University Affiliated Hospital, Chenzhou, Hunan 423000; 3Department of Critical Care Medicine, Hunan Provincial People’s Hospital, Changsha, Hunan 410005; 4Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China

Received May 11, 2017; Accepted August 10, 2017

DOI: 10.3892/ijo.2017.4119

Abstract. Glioblastoma is the most common and aggressive primary brain tumor and has a high mortality in humans. However, mechanisms and factors involved in the progression of glioblastoma remain elusive. WISP1 (WNT1 inducible signaling pathway protein 1), has been suggested to be a critical regulator of cancer development. The aim of this study was to investigate the role of WISP1 in regulating the progression of glioblastoma. Clinicopathological characteristics of glioblastoma were assessed, and higher levels of WISP1 were positively associated with advanced clinical stage and a poor prognosis. Consistently, WISP1 expression was significantly upregulated in glioblastoma tissue and cell lines compared with normal tissue and cells. Additionally, inhibition of WISP1 greatly suppressed cell proliferation, migration, and invasion and promoted apoptosis and cell cycle arrest of glioblastoma cells. Further study indicated that downregulation of WISP1 suppressed cell proliferation associated with the gene expression of c-myc and cyclin D1 and cellular signaling such as through the ERK pathway, while inhibiting epithelial-mesenchymal transition and MMP9. Finally, knockdown of WISP1 markedly suppressed in vivo tumor growth and sensitized glioblastoma cells to temozolomide. This study identified WISP1 as an oncogene in glioblastoma and suggests that WISP1 may serve as a potential molecular marker and treatment target for glioblastoma.

Introduction

Gliomas, which comprise 80% of malignant primary brain tumors (1), are recognized as the leading cause of death from central nervous system tumors (2). Gliomas are generally categorized according to the International Classification of Disease for Oncology (3rd edition) and World Health Organization grading system (3), classifying malignant behavior as grades I-IV. The overall incidence of gliomas is ~6 per 100,000 persons. The grade IV glioma, glioblastoma (4), accounts for ~45% of all gliomas and has an overall 5-year survival of <5% (1). Despite significant progress in developing surgical and adjuvant therapy, the morbidity and mortality of glioblastoma remain high. In addition to radiotherapy and surgical resection, temozolomide (TMZ) is used as the first-line chemotherapy drug for glioblastoma treatment (5). Use of TMZ has improved the overall survival and progression-free survival, but intrinsic or acquired chemoresistance is major cause of TMZ treatment failure in patients with glioblastoma (6). Identifying novel therapeutic targets is in urgent need for the diagnosis and treatment for glioblastoma.

WNT1 inducible signaling pathway protein1 (WISP1), which belongs to the CCN family (connective tissue growth factor, cysteine-rich protein, and nephroblastoma overexpressed gene), is a widely recognized downstream target gene of the Wnt/β-catenin pathway (7). While members of the CCN family are reported to regulate complex biological processes during embryogenesis, wound healing, and tissue repair (8), WISP1 was originally identified as involved in β-catenin-mediated tumorogenesis (9). WISP1 has been implicated in tumor development in multiple studies. Overexpression of WISP1 is associated with a poor prognosis in colon cancer by regulating cell adhesion (10). WISP1 promotes oral squamous cell carcinoma through angiogenesis (11). In esophageal squamous cell carcinoma, WISP1 regulates tumor cell radiosensitivity (12) and is recognized as a marker suggestive of a poor prognosis (13). These studies strongly suggest that WISP1 plays an important role in tumor development and might therefore be a potential target of tumor therapy.

Aberrant WISP1 levels were recently reported in glioblastoma. Overexpression of WISP1 enhances radiosensitivity of
glioma cells (14). Hypoxia, an important microenvironment condition for tumor formation, induces WISP1 expression in U87 human glioblastoma cells (15). These observations indicate that WISP1 is an important player in glioblastoma. However, the exact mechanisms by which WISP1 regulates the development of glioblastoma and its potential for clinical therapeutic targeting remain elusive. In the present study, we explored the role of WISP1 in regulating the growth and malignancy of glioblastoma in vitro and in vivo. We also evaluated the potential effect of WISP1 in mediating drug resistance against TMZ in glioblastoma cell lines.

Materials and methods

Tissue microarray and immunohistochemical staining. A human brain gliocytoma and normal tissue microarray containing a total of 120 samples (#TC0147; Auragene Bioscience Co., Changsha, China) was established based on 40 cases, including 5 normal samples and 35 tumor samples (2 anaplastic oligodendrogliomas, 24 astrocytomas, and 9 glioblastomas). WISP1 protein levels in the tissue specimens were determined by immunohistochemical staining. Briefly, tissue sections from the human brain tissue microarray were deparaffinized in xylene and rehydrated with decreasing concentrations of ethanol. Endogenous peroxidase activity was quenched by incubating for 15 min in 3% hydrogen peroxide. High-temperature antigen retrieval was performed in sodium citrate buffer (#P019IH; Auragene Bioscience Co.). Tissue sections were then incubated with primary WISP1 antibody (#18166-1-AP, 1:100 dilution; Proteintech, Wuhan, China) or PCNA (AM5547; Abzoom, Dallas, TX, USA) at 4°C overnight, followed by incubation with horseradish peroxidase (HRP)-conjugated secondary antibody (#SA009; Auragene Bioscience Co.). Finally, the sections were colorized with the DAB substrate kit (#P013IH; Auragene Bioscience Co.). Slides were counterstained with hematoxylin before dehydration, incubated with xylene, and mounted. The slides were evaluated by two pathologists blinded to the diagnosis for each tissue type. Scores ranged from 0 to 4, with 0 indicating no staining for WISP1 protein, 1 indicating ≤10% staining, 2 indicating 10 to ≤25% staining, 3 indicating 25 to ≤75% staining, and indicating >75 to 100% staining. In analyzing the association of WISP1 levels with clinicopathological features, a score of 0 was categorized as no expression, scores of 1 or 2 as low expression, and scores of 3 or 4 as high expression.

Clinical specimens. Normal human brain and glioma specimens were obtained from patients who underwent brain surgery at the Xiangya Hospital, Central South University from March to June 2016. None of the patients had undergone radiotherapy, chemotherapy, or other anticancer treatment before surgery. The histologic features of all specimens were evaluated by pathologists according to the WHO criteria. Written informed consent was obtained from all patients. Protocols in this study were approved by the Medical Ethics Committee of Xiangya Hospital, Central South University. Analysis of WISP1 expression levels in normal and glioblastoma tissues by bioinformatics analysis in GSE4536 from Oncomine datasets. Statistical analysis of the pathologic stage of glioblastoma patients in WISP1 expression from tissue microarray. Statistical analysis of the pathologic stage of glioblastoma patients in WISP1 expression from TCGA datasets.

Reverse transcription and quantitative real-time polymerase chain reaction. Total RNA of normal brain and glioma tissue samples were isolated using a TRIzol kit (#R1022; Invitrogen Life Technologies, Carlsbad, CA, USA). Reverse transcription of RNA into cDNA was performed with a reverse transcription kit (#K1622; Fermentans, Vilnius, Lithuania) according to the manufacturer's instructions. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed with SYBRGreen qPCR Mix (#P2092; Toyobo, Shiga, Japan) in real-time PCR system (#ABI 7300; Applied Biosystems). Primers for qPCR are as follows: WISP1 sense, 5'-ACGCAG GGAAGA AGTGTC-3'; antisense, 5'-GAGAAGCCAAGCCCATCA-3'. β-actin sense, 5'-AGGGGCCGGACTGTCATAC-3'; antisense, 5'-GGCCGGACACCATGATCCCT-3'. The β-actin gene was used as an internal control, and all qRT-PCR reactions were performed in triplicate. Relative mRNA levels of genes were calculated based on the 2-ΔΔCT method (16).

Cell culture. A normal human astrocyte cell line and human glioma cell lines including SHG-44, U-251, and U-373 MG, were obtained from Auragene Bioscience Co. Cells were cultured in RPMI-1640 medium (#SH30809.01; Hyclone, Hudson, NH, USA) supplied with 10% fetal bovine serum (#900-108; Gemini Bio Products) and 100 U/ml penicillin-streptomycin. All cells were maintained in humidified cell incubators with 5% CO2 at 37°C.

shRNA construction and cell transfection. A human WISPI shRNA (sh-WISPI) construct was generated by inserting the following targeting sequence into an shRNA vector: 5'-CCGGGCTCTATCACTGATCAAGATTACT TGGGTGTAGGACGTCTTTT-3'. A non-specific shRNA sequence was used to construct a control shRNA plasmid (sh-NC). For shRNA transfection, cells were plated at a density of 1x10^5 cells/well in 6-well plates and cultured for 24 h to reach 80-90% confluence. Culture medium was replaced with serum-free medium 4 h prior to transfection, and 4 µg/well of plasmid DNA was then transfected using Lipofectamine 2000 (#12566014; Thermo Fisher Scientific, Waltham, MA, USA) reagent according to the manufacturer's instructions. Cells were ready for further experiments after 24 h of culture in growth medium following transfection.

Western blot analysis. Protein samples from cells with or without transfection were extracted using RIPA lysis buffer (#P002A; Auragene Bioscience Co.) containing proteinase inhibitors. Sample concentrations were measured with a BCA assay. A total of 30 µg of protein from each sample was resolved on 10% sulfate-polyacrylamide gel and electrophoretically transferred onto a nitrocellulose membrane. Blots were then blocked with 5% milk and incubated with a primary antibody against the protein of interest in 3% BSA overnight at 4°C. After washing, the membranes were incubated with HRP-labeled secondary antibody, and signals were detected using an ECL chemiluminescence kit (#P001WB-1; Auragene Bioscience Co.). Densitometry analysis was evaluated by IPP6.0
were plated in 96-well plates at a density of 5x10^3 cells/well for the proliferation assay. Cells transfected with sh-NC or sh-WISP1 were used to determine the proliferation of glioma cell lines. The effect of WISP1 knockdown on cell proliferation was assessed by a cell proliferation assay. The upper chambers were precoated with an ECM matrix with serum-free medium. For the invasion assay, the upper compartments of Matrigel Transwell chambers were suspended in culture medium at a density of 1x10^6 cells/well with a total volume of 100 µl/well. When the cells were ready for the proliferation assay, 10 µl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution was added to each well and the cells were incubated for 4 h. Formazan formed in each well was solubilized by 150 µl DMSO with a 10-min gentle shake incubation. For evaluation of apoptosis, cells were treated with glacial acetic acid. The proportion of cells in early and late apoptosis was determined by flow cytometric analysis. 

**Cell proliferation assay**. The effect of WISP1 knockdown on the proliferation of glioma cell lines was determined by a cell proliferation assay. Cells transfected with sh-NC or sh-WISP1 were plated in 96-well plates at a density of 5x10^3 cells/well with a total volume of 100 µl/well. When the cells were ready for the proliferation assay, 10 µl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution was added to each well and the cells were incubated for 4 h. Formazan formed in each well was solubilized by 150 µl DMSO with a 10-min gentle shake incubation. The optical density of the solution was measured at 570 nm. 

**Annexin V-FITC/PI staining assay**. Human glioma cells with or without WISP1 knockdown were harvested using trypsin that did not contain EDTA. For evaluation of apoptosis, cells were washed with PBS and resuspended in 500 µl binding buffer and incubated sequentially with Annexin V-FITC and propidium iodide (PI) according to the manufacturer's instructions using an Annexin V-FITC-PI double staining kit. Stained cells were evaluated by flow cytometric analysis. 

**Statistical analysis**. Statistical analysis was performed using SPSS 17.0 statistical software (SPSS, Inc., Chicago, IL, USA). Data are expressed as mean ± standard error of the mean. P<0.05 was considered to indicate statistical significance. Correlation between WISP1 and clinicopathological features of patients was compared with a χ^2 test. Comparisons of WISP1 protein expression, mRNA levels, cell numbers, and tumor parameters were analyzed with a 2-tailed t-test. One-way ANOVA was performed to compare data from more than two groups. 

**Results**

Upregulation of WISP1 in glioblastoma and its association with clinicopathological features and poor survival. WISP1 expression was compared with cell growth medium (containing 10% FBS). After incubation for 24 h, cells that had migrated onto the lower membrane were stained with crystal violet solution (#C0121; Beyotime Biotech) and visualized under a microscope. Further measurement of the optical density at a wavelength of 570 nm was performed after the cells were treated with glacial acetic acid. 

**In vivo tumorigenicity assay.** To determine tumor growth in vivo, U251 cell lines transfected with Lv-sh-NC and Lv-sh-WISP1 were suspended in culture medium at a density of 1x10^7 cells/ml. BALB/c mice were acquired at 4 weeks old (certificate no. 43004700016031; Hunan SJA Laboratory Animal Co.) and kept in a 10/14-h light-dark cycle with free access to food and water. Cells were inoculated subcutaneously (4x10^6 cells/injection) into the axillary area of the mice (3 mice/group). The growth of the tumors was monitored every 3 days, with mouse bodyweight and tumor size measured and recorded. Any nodule with a diameter >0.4 cm was considered to be a tumor. The tumor volume was calculated with the following equation: V = A x B^2/2 mm^3. At the end of experiment, the mice were sacrificed and the tumors were isolated for further measurement.
expression was dramatically higher in glioblastoma tissues than in normal tissues from the Oncomine datasets (GSE4536) (9). We performed qRT-PCR assay and tissue microarray immunohistochemical staining to explore the potential involvement of WISP1 in glioblastoma. The qRT-PCR results and microarray immunohistochemical results showed that WISP1 levels were significantly higher in glioblastoma tissues compared with normal tissues (Fig. 1A and B), similar to the results of the Oncomine datasets (GSE4536). We further analyzed the correlation of WISP1 levels with clinicopathological features of glioblastoma specimens (Table I). The \( \chi^2 \) test indicated that WISP1 expression was positively associated with the clinical stage of glioblastoma (\( P=0.007 \)), but no correlation of WISP1 levels with age or sex was detected (all \( P>0.05 \)). As shown in Fig. 1C, the increased expression of WISP1 in normal tissue and in stage II, III, and IV glioblastoma tissues was specifically distributed in the cytosol. In terms of survival, patients with glioblastomas expressing lower levels of WISP1 notably lived longer than those with higher levels of WISP1 expression on tissue microarray (Fig. 1D). We also analyzed data of glioblastoma patients in TCGA datasets, with results similar to those of the Oncomine datasets (GSE4536). The \( \chi^2 \) test indicated that WISP1 expression was positively associated with the clinical stage and prognosis in glioblastoma.

We next examined the levels of WISP1 protein in normal astrocytes and glioblastoma cell lines (SHG-44, U251 and U373-MG) by western blotting. Consistent with the tissue results, the protein expression level of WISP1 (Fig. 1F) was significantly higher in glioblastoma cell lines compared with normal astrocytes. These results suggest that higher WISP1 expression was associated with the development of glioblastoma, which correlated with poor survival in patients with glioblastoma.

**Downregulation of WISP1 suppresses proliferation and promotes apoptosis and cell cycle arrest of glioblastoma cell lines.** Having confirmed that WISP1 is upregulated in glioblastoma cell lines, we hypothesized that high levels of WISP1 are important for maintaining the malignant characteristics of these cells. To test how WISP1 affects glioblastoma cell behavior, we constructed WISP1 shRNA and transfected it into U251 and U373-MG cell lines. As shown in Fig. 2A, western blot results demonstrated efficient knockdown of WISP1 to 30% of its endogenous levels.

To further assess the role of WISP1 on glioblastoma cell proliferation, MTT assay, and flow cytometry for apoptosis and cell cycle distribution assays were used. Interestingly, knockdown of WISP1 dramatically inhibited cell growth (Fig. 2B and C) as measured by MTT assays. WISP1 deficiency also resulted in increasing cell apoptosis as measured with Annexin V-FITC/PI staining (Fig. 2D). As shown in Fig. 3, transfection of the sh-NC plasmid did not alter cell populations in any phase of the cell cycle compared with non-transfected cells. Both exhibited normal distribution of nearly half the cell population in the G1 phase. However, WISP1 knockdown notably increased cell populations in the G1 phase (by ~50%), with a concomitant decrease of cell populations in the S phase. These results suggest that down-regulation of WISP1 inhibits proliferation of glioblastoma cells by arresting cell cycle progression.

**Suppression of WISP1 inhibits migration and invasion of glioblastoma cells.** Invasion of surrounding normal tissues is a critical process during tumor progression, so the migratory and invasive capacities of tumor cells are important hallmarks of tumor malignancy. We performed Transwell assays to evaluate the migration of glioma cell lines. Importantly, knockdown of WISP1 greatly inhibited the migratory ability of U251 and U373-MG cells (Fig. 4A), as demonstrated by the 60% decrease in that cell population that migrated into the lower chambers compared with control groups. Similarly,
WISP1-deficient cells exhibited a 0.5-fold decrease in invasion through Matrigel to the lower chambers in cell invasion assays (Fig. 4B).

**WISP1 downregulation improves drug sensitivity of glioblastoma cells to temozolomide.** TMZ is a recognized and effective drug to improve the outcome of glioma, but drug
Figure 4. Effect of WISP1 knockdown on migration and invasion of glioma cell lines. WISP1 knockdown in U251 and U373-MG glioma cell lines. (A) Transwell assay evaluation of cell migration and (B) invasion (with pre-coated ECM matrix gel in upper chamber). Images shown are representative observation recording of cell migrated/invaded into bottom chambers which were stained with crystal violet solution. Right panels are quantitative analysis of results from both Transwell experiments. **P<0.01, ***P<0.001, data represent mean ± SEM with 3 independent experiments.

Figure 5. TMZ drug tolerance in WISP1 knockdown glioma cell lines. (A) After knockdown of WISP1, U251 and U373-MG glioma cells were treated with indicated dosages of TMZ for 24 h, MTT assay was performed to evaluate the viability of cells. (B) Quantitative analysis of (C). U251 and U373-MG glioma cells with/without WISP1 knockdown were treated with 500 µM TMZ for 24 h, flow cytometry was used to assess apoptosis of cells. (B) Quantitative analysis of (C). *P<0.05, **P<0.01, data represent mean ± SEM with 5 independent experiments.
resistance often appears to hinder the effectiveness of TMZ. The mechanisms of TMZ resistance in glioma cells are not well understood. In order to study the potential role of WISP1 in regulating glioma drug resistance to TMZ, the cell survival rate and apoptosis were evaluated by MTT assay and flow cytometry in WISP1 downregulated cells with or without TMZ treatment. MTT assay results showed that cells with downregulation of WISP1 had a significantly lower survival rate than control groups, indicating enhanced drug sensitivity to TMZ (Fig. 5A). Flow cytometry results (Fig. 5B and C) demonstrated that WISP1 knockdown was associated with dramatically increased cell apoptosis upon TMZ treatment compared with the control group.

Potential cellular mechanisms of WISP1 function in glioma cells. To further explore the mechanisms by which WISP1 regulates cell proliferation and migration of glioma cells, associated cellular pathways that are responsible for regulating cell growth and tumor malignancy were evaluated by western blotting. Upon WISP1 knockdown, levels of c-myc protein, a key regulator of cell proliferation, greatly decreased. Cyclin D1, an important cell cycle regulation factor, as well as profoundly increased tumor suppressor P53 expression (Fig. 6A). Additionally, epithelial markers of E-cadherin were greatly increased, while the mesenchymal marker vimentin and matrix metalloproteinase 9 (MMP9) level was suppressed (Fig. 6B), indicating that WISP1 may regulate migration of glioma cells by way of epithelial-mesenchymal transition (EMT). Moreover, the extracellular signal-regulated kinase (ERK) signaling pathway, a major regulator of cell proliferation, survival, differentiation, and motility was suppressed by WISP1 knockdown (Fig. 6C). Collectively, these findings indicate that WISP1 may be involved in progression of glioma through regulating classic pathways in cell proliferation, migration, and apoptosis.

Downregulation of WISP1 suppresses glioblastoma tumor growth in vivo. In order to examine the involvement of WISP1 in tumor initiation and progression in vivo, the U251 cell line transfected with control or Lv-sh-WISP1 was evaluated for tumorigenesis capacity in BALB/c-nude mice. Interestingly, tumor weight was significantly smaller in the WISP1 knockdown group (Fig. 7A and B). Consistently, tumor weight was considerably lower in mice with WISP1
downregulation (Fig. 7C). As detected by immunohistochemical assay, the growth marker PCNA was significantly lower in the WISP1 knockdown group than in the control group (Fig. 7D). These results strongly suggest downregulation of WISP1 in glioblastoma suppresses tumor growth in vivo.

Discussion

In the present study, we explored the biological functions of WISP1 in glioblastoma. WISP1 levels were markedly increased in glioblastoma compared with normal tissue. Consistently, we found that WISP1 expression was significantly higher in glioblastoma cell lines compared with normal astrocytes. Analysis of clinical characteristics revealed that high WISP1 levels are positively associated with advanced pathologic stage and poor prognosis. Therefore, our study suggests a potential oncogenic role for WISP1 in glioblastoma. This hypothesis is further supported by our subsequent in vitro studies indicating that suppression of WISP1 in glioblastoma cells inhibited proliferation, migration, and invasion and induced apoptosis and cell cycle arrest. Mechanistically, WISP1 may function through regulation of pertinent gene signatures and critical proliferation signaling pathways. Furthermore, WISP1 suppression sensitized glioblastoma cells to TMZ treatment and significantly inhibited tumor growth in vivo.

The initiation and progression of human glioma tumors is a complex, multistep process. Even though a huge number of growth factors, oncogenes, and tumor suppressors have been identified as participating in the regulation of cancer cell survival, proliferation, and invasion, the mechanisms and factors involved in the development of glioblastoma have not been fully elucidated. The aberrant expression of WISP1 has been reported in a number of diseases (17), such as fibrotic diseases, cancer, and diabetic nephropathy and retinopathy. Interestingly, WISP1 is differentially regulated in different types of cancers (colorectal, breast, and esophageal cancer). High levels of WISP1 are associated with poor prognosis in breast (18), rectal (19), and esophageal cancers (20), while in melanoma, lower than normal WISP1 levels were found in patients with a poor outcome (21). Here, we demonstrated for the first time that WISP1 is upregulated in glioblastoma tissues and cell lines, and its expression is associated with advanced clinical stages of glioblastoma and a poor prognosis, supporting the hypothesis that WISP1 is a candidate biomarker for disease progression in glioblastoma.

Further supporting information for a link between WISP1 and glioblastoma progression comes from the in vitro and in vivo experiments in this study. Downregulation of WISP1 markedly inhibited cell proliferation, migration, and invasion, cell cycle progression, and tumorigenesis capacity. These findings are in line with previous reports of a tumor suppression effect with inhibition of WISP1 in prostate and colon cancers (10,22) and provide a plausible explanation for WISP1 regulation of the progression of glioblastoma.

Resistance to apoptosis is a fundamental part of carcinogenesis and is critical for chemotherapeutic drug resistance (23). TMZ is a DNA alkylating agent known to induce cell cycle arrest and eventually to lead to apoptosis (24). The main damage produced by TMZ is through modification of DNA or RNA at the N and O sites on guanine and the N site on adenine by the addition of methyl groups. This process produces incorrect pairing of bases, triggering the intervention of a
mismatch repair system and can be blocked by base excision repair or the activation of DNA glycosylase and demethylating enzymes (25). In our study, we demonstrated that downregulation of WISP1 improved the sensitivity of glioblastoma cell lines to TMZ treatment, suggesting that knockdown of WISP1 may have affected signaling pathways and gene expression that facilitate TMZ action. This is supported by decreased c-myc and increased p53 expression, since both have been suggested to regulate TMZ sensitivity (5,26). For example, BACH1 promotes TMZ resistance in glioblastoma by antagonizing p53 function (27).

It has been shown that EMT and the MAPK signaling pathway are associated with the progression of several cancers (28-30). MMPs promote tumor cell invasion by degrading extracellular matrix proteins and activating signal transduction cascades that increase lethality (31). EMT is a key factor contributing to cancer metastasis and chemoresistance (32). MALAT1 decreased the expression of WISP1 improved the sensitivity of glioblastoma cell lines to TMZ by promoting EMT (33). We observed a decrease in MMP9 and EMT in WISP1 knockdown cells, suggesting that WISP1 may mediate glioblastoma cell migration and invasion through regulation of cell adhesion and EMT. In addition, downregulation of WISP1 improved sensitivity of glioblastoma cells to TMZ, perhaps by suppressing EMT.

ERK signal pathway has been reported to contribute to cancer proliferation and metastasis. Silencing of AQPS inhibits cell proliferation, migration, and apoptosis of human glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34). Hirudin inhibits cell growth of glioma cells through regulation of the EGFR/ERK/p38 MAPK signaling pathway (34).

In conclusion, this study showed for the first time that WISP1 is an important regulator of glioblastoma cell proliferation, apoptosis, migration, invasion, and TMZ drug resistance. WISP1 mediates these biological processes through regulating critical gene expression and pathways that are involved in cancer progression. Based on the association of WISP1 with clinicopathological features, downregulation of WISP1 may serve as a therapeutic strategy for glioblastoma.

Acknowledgements

This study was supported by the Scientific Research Fund of Hunan Provincial Education Department (no. 15B225), Scientific Research Fund of Xiangnan University (no. 2015XB12) and Scientific Research Fund of Hunan Provincial Health and Family Planning Commission (no. C2017014).

References


